Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.39 USD
Change Today +0.02 / 0.46%
Volume 521.0K
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/2/15 - $8.47
52 Week Low
12/12/14 - $2.81
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

15 Employees
Last Reported Date: 11/13/14
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $106.0K
Compensation as of Fiscal Year 2013.

brainstorm cell therapeutics (BCLI) Key Developments

Brainstorm Cell Therapeutics Inc. Receives Notice of Allowance for its Nurown Technology Platform from Israel's Patent Office

BrainStorm Cell Therapeutics Inc. announced that it has received a Notice of Allowance from Israel's Patent Office for its patent application titled 'Isolated Population of Cells, Methods of Generating Same, and Uses Thereof in the Treatment of CNS Diseases'. This patent is held jointly with Ramot, Tel Aviv University's technology transfer company. This patent claims neurotrophic factor-secreting cells derived from mesenchymal stem cells, methods for producing those cells, and methods of using those cells for the treatment of neurologic diseases.

BrainStorm Cell Therapeutics Inc. Announces Positive Results from Preclinical Studies of NurOwn™ in the BTBR Mouse Model of Autism

BrainStorm Cell Therapeutics Inc. announced positive results from preclinical studies of NurOwn™ in the BTBR mouse model of autism. NurOwn™ cells are mesenchymal stem cells (MSCs) that have been induced, under BrainStorm's proprietary methods, to secrete a variety of neurotrophic factors. The BTBR mouse exhibits several stereotypical behavioral characteristics that resemble behaviors seen in autism spectrum disorders, including repetitive behaviors, altered social interactions, cognitive rigidity and impaired adaption to environment. These studies, conducted in collaboration with Professor Dani Offen, PhD, of Tel Aviv University Chief Scientific Advisor to BrainStorm, assessed the ability of NurOwn™ cells to affect the behavior of BTBR mice. Across all the measures, including assessments of repeated self-grooming, social interaction and cognitive rigidity, NurOwn™ cells demonstrated marked behavioral benefits in BTBR mice after a single treatment, as compared to control group, which consisted of BTBR mice treated only with vehicle. NurOwn™ cells performed particularly well in an important assessment of reversal of learning. This test evaluates the time it takes to the mice to maneuver in a water maze after the maze was first learned and then altered. In this cognitive rigidity test, NurOwn™-treated BTBR mice adapted quickly to the new conditions, taking 60% less time than the control BTBR mice to relearn the maze (p=0.016). Notably, the cognitive rigidity and social grooming behavior of the treated BTBR mice were similar to those behaviors observed in a normal mouse strain (C57/BL).

Brainstorm Cell Therapeutics Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 04:30 PM

Brainstorm Cell Therapeutics Inc. Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-19-2015 04:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Anthony Fiorino, Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $4.39 USD +0.02

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies

Industry Analysis


Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at